Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
70.10    0.10 (0.14%)
Bid:
69.80
Ask:
70.30
Spread: 0.50 (0.716%)
Market Cap: £670.92m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Directorate Change

24 Mar 2023 07:00

RNS Number : 0822U
Dr. Martens PLC
24 March 2023
 

Dr. Martens plc

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

 

Dr. Martens plc ('the Company') today announces that, following a comprehensive search and selection process, Andrew Harrison will join the Board as an Independent Non-Executive Director with effect from 1 May 2023.

 

Andrew is a managing partner at consumer brand investment firm Freston Ventures and Senior Independent Director at Ocado Group plc, proprietor of the Ocado Smart Platform and joint owner of online grocer Ocado Retail Limited, where he is also chair of the Remuneration Committee and designated Non-Executive Director for engagement with the workforce. He built his executive career over more than two decades at Carphone Warehouse, where he served as Chief Executive and Chair. As a member of the early founding team, he drove the growth and international expansion of Carphone Warehouse from a small, privately owned retailer to established market leader and FTSE constituent, subsequently leading the merger of the business with Dixons in 2014, where he was Deputy Chief Executive.

 

Paul Mason, Chairman, said:

 

"I am delighted to welcome Andrew to the Dr. Martens Board. He brings a wealth of expertise of consumer facing and technology focused businesses and a highly entrepreneurial mindset. His significant prior experience as both a Chief Executive and Non-Executive Director of large, listed companies will bolster the Board and will be invaluable to the business as we embark on the next chapter of the Dr. Martens story."

 

On joining the Board, Andrew will also become a member of the Audit, Remuneration and Nomination Committees.

 

The Company confirms that there is no further information required to be disclosed pursuant to paragraph 9.6.13 of the UK Listing Rules.

 

 

Enquiries

 

Investors and analysts

Mark Blythman, Interim Director of Investor Relations +44 7570 871207

mark.blythman@drmartens.com

Media

Gill Hammond, Director of Communications +44 7384 214248

 

H/Advisors Maitland

Rhys Jones +44 7881 996460

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

 

The Company listed successfully on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAFUDEDSEED
Date   Source Headline
31st Jul 20243:43 pmRNSTotal Voting Rights
12th Jul 202412:42 pmRNSDirector/PDMR Shareholding
11th Jul 202411:05 amRNSResult of AGM
11th Jul 20247:00 amRNSAGM Trading Update
1st Jul 202412:44 pmRNSTotal Voting Rights
18th Jun 202412:00 pmRNSBlock listing Interim Review
14th Jun 202412:51 pmRNSDirector/PDMR Shareholding
14th Jun 202412:50 pmRNSDirector/PDMR Shareholding
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 20244:35 pmRNSTechnical change in Permira ownership structure
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 202412:20 pmRNSDirector/PDMR Shareholding
12th Jun 20249:00 amRNSAnnual Financial Report
3rd Jun 20249:00 amRNSDirector/PDMR Shareholding
3rd Jun 20249:00 amRNSCompany Secretary Change
31st May 20247:00 amRNSTotal Voting Rights
30th May 20247:00 amRNSFY24 Results
14th May 20241:24 pmRNSDirector/PDMR Shareholding
10th May 20247:00 amRNSCFO start date - update
1st May 20244:14 pmRNSTotal Voting Rights
16th Apr 20247:00 amRNSCEO succession
16th Apr 20247:00 amRNSFY24 trading and FY25 outlook update
12th Apr 20243:13 pmRNSDirector/PDMR Shareholding
28th Mar 20245:56 pmRNSTotal Voting Rights
12th Mar 20243:50 pmRNSDirector/PDMR Shareholding
1st Mar 202411:19 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSCFO appointment update
14th Feb 20244:10 pmRNSDirector/PDMR Shareholding
5th Feb 20242:13 pmRNSDirector/PDMR Shareholding
1st Feb 202410:40 amRNSTotal Voting Rights
25th Jan 20247:00 amRNSQ3 FY24 Trading Statement
12th Jan 20241:58 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:13 amRNSTotal Voting Rights
15th Dec 20236:20 pmRNSTransaction in Own Shares
14th Dec 20236:15 pmRNSTransaction in Own Shares
13th Dec 20236:02 pmRNSTransaction in Own Shares
12th Dec 20236:24 pmRNSTransaction in Own Shares
12th Dec 20231:42 pmRNSDirector/PDMR Shareholding
11th Dec 20236:04 pmRNSTransaction in Own Shares
8th Dec 20236:16 pmRNSTransaction in Own Shares
7th Dec 20236:23 pmRNSTransaction in Own Shares
6th Dec 20236:08 pmRNSTransaction in Own Shares
5th Dec 20236:20 pmRNSTransaction in Own Shares
4th Dec 20236:29 pmRNSTransaction in Own Shares
1st Dec 20236:20 pmRNSTransaction in Own Shares
1st Dec 20232:08 pmRNSHolding(s) in Company
1st Dec 20238:00 amRNSBlock listing Interim Review
30th Nov 20234:08 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSHalf-year Report
20th Nov 20236:07 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.